Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Barclays Downgrades Esperion Therapeutics (ESPR) to Equalweight
June 30, 2016 6:48 AM EDTBarclays downgraded Esperion Therapeutics (NASDAQ: ESPR) from Overweight to Equalweight with a price target of $13.00 (from $28.00).
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $9.66 yesterday.
... MoreEsperion Therapeutics (ESPR) PT Cut to $25 at Needham & Company After Update, Maintains 'Buy'
June 29, 2016 2:27 PM EDTNeedham & Company analyst Chad Messer lowered his price target on Esperion Therapeutics (NASDAQ: ESPR) to $25.00 (from $77.00) but maintained a Buy rating after the company gave an update on regulatory discussions around Phase III development for bempedoic acid. Unfortunately and surprisingly the... More
JPMorgan Downgrades Esperion Therapeutics (ESPR) to Neutral
June 29, 2016 11:00 AM EDTJPMorgan downgraded Esperion Therapeutics (NASDAQ: ESPR) from Overweight to Neutral with a price target of $15.00.
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $16.18 yesterday.
... MoreRBC Capital Downgrades Esperion Therapeutics (ESPR) to Sector Perform
June 29, 2016 7:46 AM EDTRBC Capital downgraded Esperion Therapeutics (NASDAQ: ESPR) from Outperform to Sector Perform.
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $16.18 yesterday.
... MoreEsperion Therapeutics (ESPR) Provides Update on Bempedoic Acid; FDA Says Regulatory Pathway for LDL-C Lowering Indication Not Well Defined
June 28, 2016 4:06 PM EDT(Updated - June 28, 2016 4:10 PM EDT)
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a late-stage pharmaceutical company focused on developing and commercializing first-in-class oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided updates on the bempedoic acid (ETC-1002) clinical development program and regulatory plans. The clinical program has two major components: the global pivotal Phase 3 efficacy and safety studies, and the planned global cardiovascular outcomes trial (CVOT) in patients with elevated LDL-C levels who are unable to tolerate statins (statin intolerance). The Company intends to initiate global pivotal Phase 3... More
